Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603285 | 0.94 | LPL (0.47) | LPLLIPGSNCADGAT1NPC1 | |
| SCHEMBL15109046 | 0.91 | LPL (0.44) | LPLLIPGSNCADGAT1NPC1 | |
| SCHEMBL31503579 | 0.86 | TLR9 (0.52) | LPLLIPGDGAT1NPC1SMN1; SMN2 | |
| SCHEMBL3087464 | 0.84 | FGFR3 (0.59) | KDRFLT3 | |
| SCHEMBL1817315 | 0.81 | IRAK4 (0.47) | LPLLIPGSNCA | |
| SCHEMBL23018805 | 0.80 | LIPG (0.59) | LPLLIPGSNCADGAT1 | |
| SCHEMBL1814466 | 0.80 | ALDH1A1 (0.44) | LPLLIPGSNCAALDH1A1 | |
| SCHEMBL1816450 | 0.80 | LPL (0.44) | LPLLIPGSNCA | |
| SCHEMBL7604966 | 0.80 | LIPG (0.52) | LPLLIPGSNCADGAT1 | |
| SCHEMBL14022001 | 0.80 | LPL (0.39) | LPLLIPGSNCAPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2682393-A1 | Inhibitors of HCV NS5A comprising a bicyclic core. | Presidio Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2010065674-A9 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | LPL 437/4885LIPG 1416/4885SNCA 2883/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | LPL 458/4885LIPG 1401/4885SNCA 2950/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | LPL 458/4885LIPG 1401/4885SNCA 2950/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | LPL 458/4885LIPG 1401/4885SNCA 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.